207 related articles for article (PubMed ID: 19484141)
1. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Huch M; Gros A; José A; González JR; Alemany R; Fillat C
Neoplasia; 2009 Jun; 11(6):518-28, 4 p following 528. PubMed ID: 19484141
[TBL] [Abstract][Full Text] [Related]
2. uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors.
Sobrevals L; Mato-Berciano A; Urtasun N; Mazo A; Fillat C
Stem Cell Res; 2014 Jan; 12(1):1-10. PubMed ID: 24141108
[TBL] [Abstract][Full Text] [Related]
3. Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts.
José A; Sobrevals L; Miguel Camacho-Sánchez J; Huch M; Andreu N; Ayuso E; Navarro P; Alemany R; Fillat C
Oncotarget; 2013 Jan; 4(1):94-105. PubMed ID: 23328228
[TBL] [Abstract][Full Text] [Related]
4. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.
Maliandi MV; Mato-Berciano A; Sobrevals L; Roué G; José A; Fillat C
Mol Cancer; 2015 Jul; 14():146. PubMed ID: 26227809
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
[TBL] [Abstract][Full Text] [Related]
7. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
8. miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity.
Bofill-De Ros X; Gironella M; Fillat C
Mol Ther; 2014 Sep; 22(9):1665-77. PubMed ID: 24895996
[TBL] [Abstract][Full Text] [Related]
9. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
10. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
11. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
13. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
14. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D; Yanover E; Adam V; Sweeney K; Costas C; Lemoine NR; Halldén G
Clin Cancer Res; 2010 Jan; 16(2):541-53. PubMed ID: 20068104
[TBL] [Abstract][Full Text] [Related]
15. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.
Yamamoto Y; Nagasato M; Rin Y; Henmi M; Ino Y; Yachida S; Ohki R; Hiraoka N; Tagawa M; Aoki K
Cancer Med; 2017 Oct; 6(10):2385-2397. PubMed ID: 28941156
[TBL] [Abstract][Full Text] [Related]
16. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
He XP; Su CQ; Wang XH; Pan X; Tu ZX; Gong YF; Gao J; Liao Z; Jin J; Wu HY; Man XH; Li ZS
Cancer Lett; 2009 Nov; 285(1):89-98. PubMed ID: 19481338
[TBL] [Abstract][Full Text] [Related]
17. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
18. A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus.
José A; Rovira-Rigau M; Luna J; Giménez-Alejandre M; Vaquero E; García de la Torre B; Andreu D; Alemany R; Fillat C
J Control Release; 2014 Oct; 192():148-56. PubMed ID: 25037019
[TBL] [Abstract][Full Text] [Related]
19. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
20. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
